Achieve Life Sciences reports Q4 net loss $12.4M; reiterates cytisinicline NDA by end of Q2 2025

ACHIEVE LIFE SCIENCES, INC.

Cash, cash equivalents and marketable securities $34.4M as of Dec 31, 2024.
Net loss for Q4 2024 was $12.4M; full-year net loss $39.8M (pre-revenue).
NDA submission for smoking cessation cytisinicline expected end of Q2 2025; ORCA-OL enrollment complete.
Appointed Mark Oki as CFO, Dr. Kristen Slaoui and Nancy Phelan to Board.
FDA agreed Phase 3 ORCA-V2 trial design for vaping cessation; plans to initiate in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.